Alzheimer's disease (AD) is an age-related disease, which affects approximately 40% of the population at an age above 90 years. The heritability is estimated to be greater than 60% and there are rare autosomal dominant forms indicating a significant genetic influence on the disease process. Despite the successes in the early 1990s when four genes were identified, which directly cause the disease (APP, PSEN1 and PSEN2) or greatly increase the risk of disease development (APOE), it has proved exceedingly difficult to identify additional genes involved in the pathogenesis. However, several linkage and association studies have repeatedly supported the presence of susceptibility genes on chromosomes (chrms) 9, 10 and 12. The study populations have, however, mostly been of great genetic heterogeneity, and this may have contributed to the meagre successes in identifying the disease associated genetic variants. In this study, we have performed a genome wide linkage study on 71 AD families from the relatively genetically homogeneous Swedish population where it is also possible to study the genetic ancestry in public databases. We have performed nonparametric linkage analyses in the total family material as well as stratified the families with respect to the presence or absence of APOE e4. Our results suggest that the families included in this study are tightly linked to the APOE region, but do not show evidence of linkage to the previously reported linkages on chrms 9, 10 and 12. Instead, we observed the next highest LOD score on chromosome 5q35 in the total material. Further, the data suggest that the major fraction of families linked to this region is APOE e4 positive.
Introduction
Alzheimer's disease (AD) is a severe neurodegenerative disorder characterized by progressive cognitive decline. Although the genetic aetiology of the common forms of AD is complex, there are rare families with autosmal dominant inheritance patterns. Mutations in three genes amyloid precursor protein (APP), presenilin 1 (PSEN1), presenilin 2 (PSEN2) are known to cause early-onset (before the age of 65 years) AD. [1] [2] [3] [4] These genes have been identified by linkage analysis and are located on chromosomes (chrms) 21, 14 and 1, respectively. However, these genes contribute to less than 1% of all AD cases. In contrast, the only known susceptibility gene apolipoprotein E (APOE) has an attributable risk of 10-50%. 5, 6 Further, the e4 allele of the APOE gene gives a three-to five-fold increased risk for AD, but is not sufficient, nor necessary for the development of AD. To find additional AD genes, association studies in various candidate genes have been performed; however, without any conclusive results. 7 Recent whole-genome scans have shown linkage to chrms 9, 10 and 12, [8] [9] [10] which have been confirmed by fine mapping studies. [10] [11] [12] [13] [14] [15] [16] [17] Several association studies, both genome-wide and in linkage regions, have also been performed in case-control samples, which have resulted in numerous regions harbouring potential candidate genes. [18] [19] [20] [21] [22] [23] [24] Linkagebased covariate analysis has also been made to identify loci linked to AD, by including age at onset, rate of decline or presence of the e4 allele as a covariate. 17, 25 We have performed a whole-genome scan on Swedish AD families with the aim of identifying novel genes involved in AD pathogenesis. There are several strengths of studying the Swedish population. One is the publicly available genealogic information on all Swedish citizens dating back to the mid-17th century thanks to a law founded in 1686, which imposed parishes to register the Swedish population in order to find tax payers. In separate books, birth, marriage, children, death and sometimes cause of death were registered. 26 The families included in this study were traced back 3-7 generations using these parish registries. In addition, the genetic heterogeneity is likely lower in Sweden compared to many other countries such as North America used in the majority of previous linkage studies. Here we present our linkage results on 188 individuals affected by AD from 71 Swedish families.
Materials and methods

Samples
DNA was prepared according to standard procedures from whole blood. Samples from 188 individuals with AD from 71 multiplex and sib-pair families were genotyped. The average age at onset was 6976.8 years and 41% were heterozygous for the APOE e4 allele, 35% were homozygous and 24% completely lacked the e4 allele. The AD cases (men n = 65, women n = 121) were from 71 families with a history of dementia in two or more generations and with DNA samples from at least two or more living individuals affected with AD. Table 1 illustrates the number of affected individuals available for genotyping as well as the average number of known affected in each family. Families with mutations in the APP and the PSEN1 and PSEN2 genes were excluded. The AD cases were clinically evaluated and diagnosed according to NINCDS-ADRDA criteria as possible or probable AD. In 23 cases representing 18 families, the clinical diagnosis was confirmed by neuropathological examination at the Karolinska University Hospital, Huddinge, Sweden. For all affected individuals, detailed data on family history of dementia, age at onset of the disease (defined as the age when the first symptoms appeared) and its course were collected by interviewing their next of kin and by studying medical records.
An additional 19 affected, 32 unaffected siblings and 70 healthy spouses were genotyped for the markers used to fill in gaps in the genetic map, see below. All samples were collected after informed consent of the participating party or next of kin. The study was approved by the local Ethical committee at Karolinska Institutet, Huddinge, Sweden.
Genotyping
The genome scan was performed by PCR and subsequent fragment analysis of 399 fluorescently labelled microsatellite markers (Applied Biosystems Linkage Mapping Set version 2) evenly distributed with an average spacing of 10 cM across the genome. The analyses were performed on a Megabase capillary DNA sequencer (Amersham), at the Finnish Genome Center (FGC) in Helsinki. The technicians were blind to family structure. Further genotyping of eight markers to fill in gaps greater than 20 cM on chrms 2, 5, 8, 10, 14, 15 and 17 was performed by us. PCR assays were set up in 10 ml volumes using 0.4 mM primers, 0.2 mM dNTPs, 1.5 mM MgCl 2 , 0.25 U AmpliTaq Goldt and 30 ng DNA. The fragments were separated and genotypes were scored using the ABI PRISM s 3100 Genetic Analyser (Applied Biosystems) and GeneMappert version 2.0.1 programme, respectively. The CEPH DNAs: 133101, 133102 and 134702 were genotyped to ensure correct scoring of alleles.
Statistical analysis
Linkage analysis. We used the programme Allegro (version 1.2) 27 to calculate nonparametric allelesharing LOD scores for multipoint (mpt) and single point (spt) analysis as well as LOD exact P-values (pointwise P-values). It was performed on a Unix Sun Solaris platform using the exponential allele-sharing model 28 and scoring function 'all' 29, 30 with family weight = 0.5, as recommended in the Allegro manual to adjust differences in pedigree size. Due to computational limitations (which occurred because some of the families studied were > 26 bits), some 'uninformative' siblings in the largest families were removed from this analysis. Model-free Allegro calculations were first made on the whole set of 71 families and secondly after stratification according to APOE e4 status. In total, 46 families were stratified into the APOE e4 positive group 'e4 pos families', where all affected had at least one e4 allele, and 25 families into the APOE e4 negative group 'e4 neg families', where at least one affected completely lacked an APOE e4 allele. In the e4 neg families, affection status for individuals carrying an e4 allele was set as unknown. Thereby, these individuals do not contribute to the LOD score but they add information about phase.
Microsatellite allele frequencies were calculated from the genotypic data of the analysed AD families together with genotypes from nondemented Swedish individuals, who were investigated earlier at the FGC in Helsinki. The nondemented individuals were anonymous to us and we had no clinical information on these samples. Thus, for most markers 1000 to 1200 alleles were available. Genetic maps and intermarker distances were obtained from the deCODE map 31 or the Marshfield Center for Medical Genetics map (http://research.marshfieldclinic.org/genetics/). The genotypes obtained from filling gaps on chrms 2, 5, 8, 10, 14, 15 and 17 were included in the Allegro calculations, including the genotypes from the additional 121 samples (see above in Samples section). Simulations. Simulation analysis with 1000 iterations was performed under the null hypothesis of no linkage anywhere in the genome. The same marker maps, allele frequencies and family structures as in the linkage analyses were used. Three different simulation sets were made: the total set of 71 families, the APOE e4 negative and the APOE e4 positive families. Genotypes were simulated for all chromosomes except the X chromosome. We used the simulated LOD scores to estimate the global significance of our three highest observed LOD scores.
Genealogy
Sweden offers good opportunities for genealogical research thanks to a law from 1686, which imposed parishes to register the Swedish population in order to find taxpayers. In separate books, birth, marriage, children, death and sometimes cause of death were registered. Church records at Arninge Riksarkiv, Sweden were investigated for the families included in this study.
Results
Successful genotyping was performed on 365 markers with an average inter marker distance of 8.97 cM. When failed markers were excluded, the success rate for the genotyping at FGC was 95.5%, after Mendel and haplotype checking and 87% including failed markers. After we filled in the gaps on chrms 2, 5, 8, 10, 14, 15 and 17 there remained gaps greater than 20 cM on chrms 6, 13, 18, 21 and the X chromosome.
Simulations. Simulations were used to estimate global P-values. We have used the threshold levels suggested by Lander and Kruglyak 32 to define significant and suggestive linkage in this study. As shown in Table 2 , the highest LOD score on chromosome 19q13 reached a significant global Pvalue for the total material as well as the APOE e4 positive families. The second highest LOD score (2.40) located in 5q35.2 is suggestive of linkage.
Linkage calculations. When the whole set of families was analysed, a significant LOD score of 4.84 (pointwise P = 1.1 Â 10
À6
, simulated global P-value 0.01) was found close to marker D19S902 in the region of the APOE gene in 19q13.33, Table 2 . This was the only LOD score that reached a global significant linkage value according to Lander and Kruglyak's criteria. 32 The e4 pos group of families also obtained its highest linkage value in the same region. Thus, the linkage peaks most probably reflect the genetic effect of the APOE gene. The reported values are uncorrected for multiple testing. The second highest LOD score for the 71 families was 2.40 (pointwise P = 4.2 Â 10
À4
) obtained in 5q35.2 with marker D5S498. This LOD score reached the level of suggestive linkage as estimated by our simulation analysis. The 5q35 region has previously been reported to be linked to LOAD sib-pairs. 8, 10 The major contribution of the peak comes from the e4 pos substrata, which obtained its third highest LOD score of 1.91 (pointwise P = 0.0014) for the mpt analysis, and a LOD of 1.91 in the spt analysis at marker D5S498.
When the sample was stratified according to APOE e4 status, the e4 pos families (n = 46) showed significant linkage to 19q13.32 (LOD = 4.34, pointwise P = 3.70 Â 10
À6
, simulated global P-value = 0.006) at position 71.5 cM, which is between marker D19S420 and D19S902. The second highest LOD score in the APOE e4 subgroup was suggestive of linkage with marker D4S406 in 4q25 (mpt LOD = 2.00, spt LOD = 2.35).
The highest multipoint LOD score observed in the e4 neg subgroup approached the level of global suggestive linkage (LOD = 1.36, pointwise P = 0.0063 in 19q13).
Genealogy
Genealogic studies of church records identified more than 3000 ancestors dating back 3-7 generations for the families. Research in families descending from the same geographical areas made it possible to make five large families out of 12 smaller families (data not shown). However, the disease did not always Table 2 The two highest multipoint and single-point nonparametric LOD scores in the complete family material, the APOE e4 positive and APOE e4 negative families, respectively, are listed with the global significance values estimated by simulation segregate through the common ancestor, which is not unexpected for a complex disease. In some families, there was evidence of consanguinity and the inheritance pattern of AD in some of these and other families where the disease is present in both parental lineages may be explained by an autosomal recessive inheritance (data not shown).
Discussion
We present the results on the first whole-genome scan on Swedish familial AD sib-pairs, trios and multiplex families. We reach statistically significant linkage (LOD = 4.84) in chromosome 19q13 close to the APOE gene. The whole-sample set, including 71 families, generated its highest multipoint linkage peak at location 73.06 cM, close to D19S902, located approximately 3 Mb downstream of APOE, whereas the APOE e4 positive substratum reached its maximum close to D19S420, approximately 1.5 Mb upstream of the APOE locus. Long haplotype blocks without recombination were seen in all families linked to this region, which makes it difficult to determine if APOE alone contributes to the linkage peak or if there are additional AD loci in the neighbouring region. The possibility of two different genes involved in the AD disease process on chrm 19 has previously been proposed 33 and shown. 34 With a denser map of markers, we hope to be able to determine if other genes in the region are involved in the pathogenesis of AD in our families. For the APOE e4 negative families, the strongest signal in the multipoint linkage analysis was also obtained in the APOE region in 19q13; however, it did not reach the level of suggestive linkage. This is not surprising, given the small number of families in this substratum. In order to achieve significant LOD scores, it would be necessary to increase the number of families and/or family members in this group.
Besides the strong linkage to the known susceptibility gene APOE in chr 19, we also obtained suggestive linkage (LOD = 2.40) to chromosome 5 in the whole material with the peak at D5S498. This marker located in 5q35.2 showed signs of linkage also in the APOE e4 positive substrata, however, nonsignificant. Earlier reports of linkage in 5q35 have been made with a peak at marker D5S211, only 2 cM centromeric to our finding. 8 Candidate genes in 5q35 are among others HMP19, the dopamine receptor (DRD1), histamine receptor (HRH), complexin-2 (CPLX2) and the beta-synuclein gene (SCNB).
The suggestive linkage in the APOE e4 positive substrata at 4q24-25 colocalizes with the recently identified amyloid associated protein CLAC. 35, 36 The alpha-synuclein gene, which is associated with Parkinson's disease and furthermore has been reported to be associated with AD is located in 4q22, which is proximal to our linkage peak. 37 Two groups have previously reported linkage to the more distal region 4q32 on the chromosome. 8, 13 No evidence of linkage was found in the present study to any of the earlier reported AD linkage regions on chrms 9, 10 and 12. Nor did we find linkage to APP, PSEN1 or PSEN2 on chrms 21, 14 and 1, respectively, which is not unexpected since families with identified mutations in these genes had been excluded from the study.
In conclusion, our results differ from previous performed genome scans on familial AD, which clearly illustrates the heterogeneity of the disease. This could reflect genetic differences between populations and can be supported by the fact that previous reported genome scans have mostly been performed on American Caucasians. Concerning genetic differences between populations, we have reported that PSEN1 mutations are less frequent (3%) in our Swedish early onset AD cases 38 compared to other studies, which have a mutation detection rate of 20-50%. 39 This is the first genome scan performed on Swedish AD families. It is possible that the Swedish population is homogeneous enough to identify genes for complex diseases such as AD in parallel to the successes in Finland and Iceland. One of the great advantages is the genealogic resources, which allow for the identification of common ancestries between families. In addition, we expect to find founder effects in the northern parts of Sweden, as many of the families have lived in the same region for several generations. Future plans are to continue the genealogical investigations to try to find common ancestors in our AD families. Additional analysis is now ongoing in an extended family material, using additional families and by adding more affected individuals to existing pedigrees, as well as using a denser map of microsatellite markers to identify new AD genes and thus the present results should be considered to be preliminary.
